Columbus, Ohio–(business wire)– The Battelle, AmplifyBio, and Andelyn Biosciences teams have won an eight-year, $149 million Indefinite Delivery, Indefinite Quantity (IDIQ) contract vehicle seat at the National Institute of Neurological Disorders and Stroke. As one of his multiple award-winning IDIQ prime contractors, the team will work for the translational development of therapeutic biotechnology products in the National Institutes of Health’s drug discovery and development program to address neurological disorders. provides manufacturing and non-clinical support for
Drew Cawthon, Business Line Director of Life Sciences Research at Battelle, said: “We are investigating new and novel ways to treat rare diseases for which there are no effective treatments yet.”
AmplifyBio EVP and Chief Commercial Officer Jerry Hacker said: “This highlights the kinds of collaborations possible in Central Ohio’s growing life sciences hub. We look forward to accelerating treatment.”
Andelyn Chief Commercial Officer Eric Blair added: At Andelyn, we are committed to making an impact in the manufacturing of therapeutics, especially when it comes to treating rare diseases. We look forward to working with our partners to bring hope to affected patients. ”
Battelle not only offers assay support and integration services to support regulatory approvals, but also decades of federal contracting experience underpinning its position as prime contractor. Beyond significant technical and program management expertise, the team is unique in that all team members are local to Central Ohio.
“What we have in Central Ohio is comparable to what is available on the national or international stage,” said Brian Burbach, a Battelle chemist in the Life Sciences Research Business Unit. “The specific scope of work was a great opportunity to bring the Central Ohio team together.”
All three teams actively collaborated on the winning proposal. When bidding on task orders, we expect each partner to receive a similar share of work, relying on each organization’s differentiated strengths to meet client needs.
About Battelle
Every day, the people of Battelle apply technology to solve the most important things. At major technology centers and national laboratories around the world, Battelle conducts research and development, designs and manufactures products, and provides critical services to government and corporate customers. Founded in 1929 and headquartered in Columbus, Ohio, Battelle serves the national security, health and life sciences, energy and environmental industries. For more information, visit battelle.org.
About Andelyn Biosciences, Inc.
Andelyn is a biopharmaceutical CDMO Pioneering Solutions™ that Turn Hope into RealityHeadquartered in Columbus, Ohio, USA, Andelyn’s capabilities range from viral vector process and analytical development, small to large-scale adherent and suspension-based GMP drug substance manufacturing (up to 2000L), and pharmaceutical manufacturing services. range.Over 20 years of experience in viral vector manufacturing [andelynbio.com], Andelyn provides clients with direct access to globally recognized thought leaders who have enabled more than 75 global clinical trials. With experience gained from over 400 of his cGMP clinical batches and over 2000 of his research-grade production, Andelyn provides clients with end-to-end manufacturing services, advanced quality systems, full regulatory support, and supply his It provides vertical integration of the chain. Andelyn will begin operations at his state-of-the-art 200,000-square-foot commercial manufacturing facility in September 2022, expanding capacity to more than 14 of his production suites for new program customization and technology transfer programs Did. Andelyn is one of the few to offer clinical through commercial-scale capabilities that will help fulfill his Andelyn mission of accelerating the development and manufacturing of innovative therapies to bring more treatments to more patients. He is one of the CDMO’s. Andelyn is owned and supported by Nationwide Children’s Hospital and Pall-Cytiva, part of the Danaher Corporation.
For more information, please visit https://andelynbio.com/. [andelynbio.com].
About AmplifyBio
AmplifyBio is a leading preclinical CRO focused on toxicology, safety and pharmacology studies, advancing therapeutics to improve human health. Spun out of Battelle in May 2021, his AmplifyBio mission is to continue to deliver superior CRO research services in an agile environment fit for commercial goals, expanding analytical capabilities to drive the dynamics of advanced therapeutics development. It is to meet the needs. AmplifyBio’s clients draw from decades of experience in the design and execution of GLP and non-GLP studies and rapid investments in technology, expertise and infrastructure that provide key elements of a reliable preclinical partnership. We enjoy the peace of mind that comes with it.
